| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8219526 | International Journal of Radiation Oncology*Biology*Physics | 2014 | 9 Pages |
Abstract
NCRT with concurrent S-1/irinotecan produced high response rates and excellent long-term survival, with acceptable adverse effects in patients with rectal cancer. ypN2 is a strong predictor of dismal outcomes, and a combination of ypT and tumor location can identify high-risk patients among those with ypN0/1 disease.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Takatoshi MD, PhD, Keishi MD, PhD, Takeo MD, PhD, Akira MD, Masanori MD, PhD, Masahiko MD, PhD, FACS,